Ophthalmology Contract Research Organization Global Market Report 2025

The ophthalmology contract research organization market size has grown strongly in recent years. It will grow from $2.73 billion in 2024 to $2.97 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. This historical growth has been fueled by factors such as a higher prevalence of vision-related diseases, an aging global population, expanded ophthalmic drug development activities, increased globalization of clinical research, and the rising impact of chronic illnesses like diabetes.

The ophthalmology contract research organization market size is expected to see rapid growth in the next few years. It will grow to $4.07 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. This projected growth is driven by expanding use of decentralized clinical trial models, increased R&D activity in ophthalmic medical devices, greater funding in precision medicine initiatives, heightened interest in pediatric eye care research, and rising venture capital investments in eye health startups. Emerging trends anticipated in this period include progress in imaging technologies, development of AI-powered diagnostic solutions, use of remote monitoring systems, innovations in 3D retinal imaging, and integration of cloud-based platforms for trial management.

The growing prevalence of eye disorders is anticipated to drive the expansion of the ophthalmology contract research organization market in the coming years. Eye disorders encompass a broad spectrum of conditions that impact the structure or functionality of the eye, potentially leading to vision impairment or discomfort. The rise in these conditions is primarily attributed to an aging population, as age-related eye diseases such as cataracts, glaucoma, macular degeneration, and diabetic retinopathy become increasingly common. Ophthalmology contract research organizations contribute to the advancement of eye disorder treatments by offering specialized clinical research services that accelerate the development, testing, and regulatory approval of innovative ophthalmic therapies. For example, in September 2023, the Association of Optometrists, a UK-based professional body, reported that England documented 22,552 new certifications for vision impairment in 2022, including 1,344 cases linked to diabetic eye disease, 3,614 to glaucoma, and 10,865 to age-related macular degeneration. Consequently, the increasing prevalence of eye disorders is fueling the growth of the ophthalmology contract research organization market.

Leading companies in the ophthalmology contract research organization market are prioritizing the development of innovative solutions, such as integrated trial platforms, to streamline the execution of clinical studies and improve data management capabilities. These integrated trial platforms are unified digital systems that manage every aspect of clinical trials, including patient recruitment, data collection, and regulatory compliance. They allow ophthalmology CROs to enhance operational efficiency, minimize errors, and expedite the development of new ophthalmic treatments. For instance, in September 2024, Lindus Health Limited, a biotechnology firm based in the UK, introduced its All-in-One Ophthalmology CRO, featuring a proprietary integrated trial platform called Citrus. This platform consolidates essential trial components - such as patient recruitment, electronic data capture (EDC), eConsent, patient scheduling, and clinical trial management system (CTMS) functions - into a customizable digital ecosystem. This integration enhances workflow efficiency, reduces the likelihood of data errors, and ensures adherence to regulatory standards throughout the clinical trial process.

In January 2024, Iuvo Bioscience LLC, a US-based contract research organization with a focus on ophthalmology, acquired Promedica International for an undisclosed amount. This acquisition is aimed at expanding Iuvo BioScience’s ophthalmic clinical CRO services by incorporating Promedica International’s specialized capabilities, resulting in a comprehensive platform that supports ophthalmic research from preclinical through all clinical development phases. Promedica International is a US-based CRO that provides clinical research services to the medical device, biotechnology, and pharmaceutical industries, with a strong emphasis on ophthalmology.

Major players in the ophthalmology contract research organization market are IQVIA Holdings Inc., Eurofins Scientific SE, Syneos Health Inc., Charles River Laboratories International Inc., Parexel International Corporation, Fortrea Holdings Inc., Medpace Holdings Inc., PSI CRO AG, Worldwide Clinical Trials, The Emmes Company LLC, TFS HealthScience, QPS Holdings LLC, ProTrial Research Inc., Lexitas Pharma Services Inc., Covance Inc., Cliantha Research Limited, Trial Runners, Iris Pharma, WuXi AppTec Co. Ltd., ORA Inc., Novotech Health Holdings Pty Limited.

North America was the largest region in the ophthalmology contract research organization market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in ophthalmology contract research organization report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ophthalmology contract research organization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An ophthalmology contract research organization (CRO) is a specialized entity that assists pharmaceutical, biotechnology, and medical device companies in conducting research and clinical trials focused on eye disorders and vision-related treatments. These CROs provide either comprehensive support or targeted assistance across various stages of ophthalmic drug, biologic, or device development, ranging from preclinical evaluations to regulatory submissions and post-marketing follow-ups.

The core services offered by ophthalmology contract research organizations include early phase development, clinical research, laboratory services, and regulatory consulting. Early phase development in the ophthalmology sector involves foundational testing and research to determine the safety, dosage, and initial efficacy of novel drugs and devices prior to large-scale clinical trials. The therapeutic approaches used encompass conventional treatments, anti-inflammatory strategies (such as corticosteroids, non-steroidal anti-inflammatory drugs, and other related agents), antioxidant therapies, and cutting-edge interventions. These services are designed for diverse end-users, including pharmaceutical and biopharmaceutical firms, medical device manufacturers, and academic research institutions.

The ophthalmology contract research organization market research report is one of a series of new reports that provides ophthalmology contract research organization market statistics, including ophthalmology contract research organization industry global market size, regional shares, competitors with an ophthalmology contract research organization market share, detailed ophthalmology contract research organization market segments, market trends and opportunities, and any further data you may need to thrive in the ophthalmology contract research organization industry. The ophthalmology contract research organization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ophthalmology contract research organization market includes revenues earned by entities by providing services such as preclinical research, clinical trial management, regulatory affairs, data management and biostatistics, medical imaging and reading, post-marketing surveillance, and strategic consulting. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.